維生素 B6（吡哆醇 / 比哆醇 / Pyridoxine / P-5-P） Vitamin B6 (Pyridoxine / Pyridoxal-5'-Phosphate) × 同半胱胺酸（高同半胱胺酸血症與心血管預防）
結論：主流反證據
這是典型的「生化指標改善、臨床終點不變」案例。
D 🔴 D 反證據 主流反證據 🚨 high — heavy affiliate marketing in TW community
這是典型的「生化指標改善、臨床終點不變」案例。
B6（含 B6 之 B 群組合）能可靠降低血漿 homocysteine 約 25%（surrogate 證據成立），但 ≥7 個 high-quality RCT（VITATOPS n=8,164、HOPE-2 n=5,522、NORVIT n=3,749、VISP n=3,680、SEARCH n=12,064）及兩項頂級統合分析（Clarke IPD MA n=37,485、Cochrane 2017 n=71,422）一致顯示對 hard CV endpoints（MI、CV 死亡、全因死亡）無益處。
NORVIT 的 B6 單獨組（40 mg）甚至無法有效降 Hcy；HOPE-2 B6 50 mg 組合的 unstable angina 住院 RR 1.24（CI 1.04-1.49）顯示潛在傷害訊號。
AHA 2007 起、2017 ACC/AHA 風險評估、2019 ACC/AHA 一級預防、2021 ESC/AHA-ASA 二級中風預防指引均明確 against B6/B 群作為 CVD 預防。
Mayo/Cleveland/Harvard 三家學術醫療一致認定 biochemical effect 不等於 clinical benefit。
對於「以降 Hcy 預防 CVD」這個明確的臨床聲稱，證據已成熟到 D 等級反證據。
⚖️
評分透明度
所有分數由 7 層證據引擎計算，過程公開可查原始分數 0.29
D
C
B
A
S
← 反證據 / 無效有效 / 強證據 →
最終評級
D · 主流反證據
信心度
76%
證據方向大致一致
證據層級
E1
Cochrane 高品質系統性回顧／統合分析
▸查看完整決策路徑（audit trail）
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.286
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 高階證據未達主導 (0 positive vs 1 negative)，由 raw_score 決定
- tier_strict_requirement_check — Tier 條件達標，未降階
- detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status
B vitamins in patients with recent transient ischaemic attack or stroke in the VITAmins TO Prevent Stroke (VITATOPS) trial
結論：Daily B6 25 mg + folate 2 mg + B12 0.5 mg lowered homocysteine but did not reduce the primary composite of stroke, MI, or vascular death (15% B-vitamin arm vs 17% placebo; RR 0.91, 95% CI 0.82-1.00, p=0.05). Individual endpoints (stroke, MI, vascular death) all non-significant on their own. Largest stroke-specific trial of B6-containing regimen; net result null on hard outcomes despite Hcy reduction.
前往 PubMed
Homocysteine lowering and cardiovascular events after acute myocardial infarction (NORVIT trial, Bonaa et al., NEJM)
結論：Critical for B6-alone evidence: the B6-monotherapy arm (40 mg pyridoxine alone, no folate/B12) produced essentially NO homocysteine lowering and showed no benefit on the primary composite (17.1% B6-alone vs 16.2% placebo; RR 1.14, 95% CI 0.93-1.39). The triple-combination arm (folate + B12 + B6) showed a borderline harmful signal (RR 1.22, p=0.05). Conclusion: B6 alone is biochemically ineffective at lowering Hcy and provides no CV benefit; adding high-dose B6 to folate + B12 does not improve clinical outcomes and may worsen them.
前往 PubMed
Homocysteine lowering with folic acid and B vitamins in vascular disease (HOPE-2 trial, Lonn et al., NEJM)
結論：Combination including B6 50 mg reduced mean plasma homocysteine 2.4 µmol/L. Primary composite RR 0.95 (95% CI 0.84-1.07, p=0.41) - null. Stroke modestly reduced (RR 0.75, 95% CI 0.59-0.97) but hospitalization for unstable angina significantly increased (RR 1.24, 95% CI 1.04-1.49). B6 contribution to net effect cannot be isolated from folate/B12 in this design. Trial included high-dose B6 (50 mg) without evidence of clear benefit on hard endpoints.
前往 PubMed
Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death (VISP trial, Toole et al., JAMA)
結論：High-dose regimen including B6 25 mg lowered homocysteine ~2 µmol/L more than low-dose arm. Recurrent ischemic stroke equivalent between arms (HR 1.0, 95% CI 0.8-1.3); composite vascular endpoint also null (HR 1.0, 95% CI 0.8-1.1). The B6 dose differential (25 mg vs 0.2 mg) is large but contributed minimally to Hcy lowering (folate is the dominant Hcy-lowering agent). No clinical benefit attributable to B6 dose.
前往 PubMed
Effects of homocysteine-lowering with folic acid plus vitamin B12 vs placebo on mortality and major morbidity in myocardial infarction survivors (SEARCH trial, Armitage et al., JAMA)
結論：Included as comparison: SEARCH used folate + B12 WITHOUT B6 and reduced homocysteine by 28% (3.8 µmol/L) - confirming folate + B12 (not B6) is the active Hcy-lowering combination. Primary major vascular event RR 1.04 (95% CI 0.97-1.12, p=0.28) - null. This trial demonstrates that excluding B6 does not reduce Hcy-lowering effect, reinforcing that B6 contributes negligibly to homocysteine reduction in repleted populations.
前往 PubMed
Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: Meta-analysis of 8 randomized trials involving 37 485 individuals
結論：Allocation to B-vitamin supplementation (most regimens included B6 20-50 mg) reduced homocysteine 25% on average. No effect on major vascular events (RR 1.01, 95% CI 0.96-1.07), coronary events (RR 1.01, 95% CI 0.95-1.07), stroke (RR 0.96, 95% CI 0.87-1.06), cancer (RR 1.05, 95% CI 0.98-1.13), or all-cause mortality (RR 1.02). Subgroup analysis: no benefit detected for any trial regimen variant including those with high-dose B6. Definitive null result across 37,485 participants.
前往 PubMed
Homocysteine-lowering interventions for preventing cardiovascular events (Cochrane systematic review, Marti-Carvajal et al.)
結論：Pooled 15 RCTs (n=71,422) including all major B6-containing regimens: no effect on non-fatal/fatal MI (RR 1.02, 95% CI 0.95-1.10; high-quality evidence), all-cause mortality (RR 1.01, 95% CI 0.96-1.06), or cardiovascular mortality. Borderline stroke reduction (RR 0.90, 95% CI 0.82-0.99) driven by trials in non-fortified regions (especially Chinese CSPPT, which used folate alone WITHOUT B6). Authors conclude no convincing evidence supporting homocysteine-lowering (including B6-containing regimens) for CV event prevention.
前往 PubMed
L4a US FDA
支持
PYRIDOXINE — CAS 65-23-6 — SCOGS no. 100 — 21 CFR 101.9, 170.3(o) — Generally Recognized as Safe (referenced via SCOGS); permitted use: NUTRIENT SUPPLEMENT. 來源↗
L4b EU EFSA
支持
the Panel established a tolerable upper intake level (UL) for vitamin B6 of 12.5 mg/day for adults, including pregnant and lactating women 來源↗
L4c UK NHS
謹慎
Taking 200mg or more a day of vitamin B6 can lead to a loss of feeling in the arms and legs known as peripheral neuropathy. ... Do not take more than 10mg of vitamin B6 a day in supplements unless advised to by a doctor. 來源↗
L4d TW TFDA / 衛福部
支持
維生素B6成人每日建議攝取量為1.5毫克，上限攝取量為80毫克 來源↗
L4e WHO
謹慎
From 1 June 2027, oral preparations containing 50 mg or less per recommended daily dose will continue to be available for general retail sale. Oral preparations containing more than 50 mg but not more than 200 mg per recommended daily dose will be available over the counter with the advice of a pharmacist. Oral preparations containing more than 200 mg per recommended daily dose will continue to… 來源↗
L5a NIH Office of Dietary Supplements
支持
The American College of Obstetrics and Gynecology (ACOG) recommends monotherapy with 10–25 mg of vitamin B6 three or four times a day to treat nausea and vomiting in pregnancy. 來源↗
L5b Mayo Clinic
中性
— 本適應症無對應資料
L5c Cleveland Clinic
謹慎
L5d Harvard Health
中性
L5e Specialty Society (condition-mapped)
反對
Current guidelines, such as the American Heart Association (AHA), do not recommend neither B-vitamin supplementation nor routine screening for elevated homocysteine levels. 來源↗
PTT · Dcard · Mobile01 彙整自公開論壇討論，非統計抽樣，僅反映社群風向。
廣告 / 業配密度 極高
低中高
📍立場總覽
PTT/Dcard/Mobile01 幾乎沒有「單獨補 B6 用於降同半胱胺酸 / 心血管預防」的鄉民實測討論。社群只有泛 B 群保健品的推薦話題（多為業配/聯盟行銷整理文），同半胱胺酸與 B6/葉酸/B12 的關聯只出現在醫療衛教與檢驗單位文章，非社群經驗。屬冷門配對，無在地真實使用心得可萃取。
💬社群實感
無共識（社群無針對 B6 降同半胱胺酸的實測討論）
- 葉酸（folic acid）治療
- 維生素 B12 合併治療
查看 ClaimReview 結構化資料 (JSON-LD)
{
"@context": "https://schema.org",
"@type": "ClaimReview",
"url": "https://gpt-dict.com/claim/CLM-COND-homocysteine-INT-vitamin-b6-001/",
"datePublished": "2026-06-01",
"author": {
"@type": "Organization",
"name": "gpt-dict.com",
"url": "https://gpt-dict.com"
},
"claimReviewed": "維生素 B6（吡哆醇 / 比哆醇 / Pyridoxine / P-5-P）能改善同半胱胺酸（高同半胱胺酸血症與心血管預防）",
"inLanguage": "zh-TW",
"itemReviewed": {
"@type": "Claim",
"appearance": []
},
"reviewRating": {
"@type": "Rating",
"ratingValue": 1,
"bestRating": 5,
"worstRating": 1,
"alternateName": "🔴 D 反證據"
}
}